Thalidomide-O-amido-PEG-C2-NH2 is primarily utilized in the field of targeted drug delivery and proteolysis-targeting chimeras (PROTACs). Its structure allows for the conjugation of thalidomide, a molecule known for its ability to bind cereblon, with a polyethylene glycol (PEG) linker and an amine group. This design enhances solubility and biocompatibility, making it suitable for attaching to therapeutic agents or targeting moieties. The compound is often employed in the development of PROTACs, where it facilitates the degradation of specific proteins by recruiting E3 ubiquitin ligases. Additionally, its PEG linker improves pharmacokinetic properties, such as prolonged circulation time and reduced immunogenicity, making it valuable in creating advanced therapeutics for cancer, autoimmune diseases, and other conditions requiring precise protein modulation.